Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 4/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20943298 | 1.00 | CFD (0.46) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL30446181 | 1.00 | CFD (0.46) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL14691470 | 0.84 | CFD (0.45) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL15675244 | 0.84 | CFD (0.49) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL15675029 | 0.83 | CFD (0.48) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL10840143 | 0.81 | ADRA2A (0.50) | CFDADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL31074205 | 0.81 | CES2 (0.46) | ADRB1ADRA2AADRB3ADRA2BADRA2C | |
| SCHEMBL31074207 | 0.81 | KCNH2 (0.48) | ADRB1ADRB2AOC3CYP2D6NFKB1 | |
| SCHEMBL3190822 | 0.81 | KCNH2 (0.48) | ADRB1ADRB2AOC3CYP2D6NFKB1 | |
| SCHEMBL7154532 | 0.81 | ADRA2A (0.50) | CFDADRB1ADRA2AADRB3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024183772-A1 | CYCLIC PHOSPHATE COMPOUND AS DRUG FOR REGULATING CHOLESTEROL METABOLISM VIA LIVER DELIVERY AND USE | 浙江柏拉阿图医药科技有限公司 | 2024-09-12 | — | — | WO | disclosed |
| EP-3476854-B1 | ANTIVIRAL PRECURSOR DRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USE THEREOF | ZHEJIANG PALOALTO PHARMACEUTICAL TECH CO LTD (CN) | 2021-05-12 | — | — | EP | disclosed |
| CN-107540710-B | Liver delivery antiviral prodrug nucleoside cyclic phosphate ester compound and application thereof | 浙江柏拉阿图医药科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10668090-B2 | Liver specific delivery-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof | ZHEJIANG PALO ALTO PHARMACEUTICALS, INC (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190125771-A1 | LIVER SPECIFIC DELIVERY-BASED ANTIVIRAL PRODRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USES THEREOF | ZHEJIANG PALO ALTO PHARMACEUTICALS,INC (CN) | 2019-05-02 | — | — | US | disclosed |
| EP-3476854-A1 | LIVER DELIVERY-BASED ANTIVIRAL PRECURSOR DRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USE THEREOF | Zhejiang Paloalto Pharmaceutical Technology Co Ltd (CN) | 2019-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125771-A1 | LIVER SPECIFIC DELIVERY-BASED ANTIVIRAL PRODRUG NUCLEOSIDE CYCLOPHOSPHATE COMPOUND AND USES THEREOF | SLC10A1, NPC1, NPC1L1 | CFD 2694/4885ADRB1 3278/4885ADRA2A 4402/4885 |
| US-10668090-B2 | Liver specific delivery-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof | SLC10A1, NPC1, NPC1L1 | CFD 2694/4885ADRB1 3278/4885ADRA2A 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.